| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:42 UTC |
|---|
| HMDB ID | HMDB0014677 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Ciprofloxacin |
|---|
| Description | Ciprofloxacin, also known as CPFX or ciprinol, belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions. Ciprofloxacin is a very strong basic compound (based on its pKa). Ciprofloxacin is a potentially toxic compound. A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively. |
|---|
| Structure | OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) |
|---|
| Synonyms | | Value | Source |
|---|
| 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid | ChEBI | | 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid | ChEBI | | 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid | ChEBI | | 1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID | ChEBI | | 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid | ChEBI | | 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid | ChEBI | | 1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid | ChEBI | | Ciprofloxacine | ChEBI | | Ciprofloxacino | ChEBI | | Ciprofloxacinum | ChEBI | | CPFX | Kegg | | Cipro | Kegg | | 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate | Generator | | 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate | Generator | | 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate | Generator | | 1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate | Generator | | 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate | Generator | | 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate | Generator | | 1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate | Generator | | Ciprofloxacin monohydrochloride | HMDB | | Ciprofloxacina | HMDB | | Ciprofloxacin hydrochloride | HMDB | | Ciprofloxacin hydrochloride anhydrous | HMDB | | Monohydrochloride monohydrate, ciprofloxacin | HMDB | | Ciprinol | HMDB | | Ciprofloxacin monohydrochloride monohydrate | HMDB | | Hydrochloride anhydrous, ciprofloxacin | HMDB | | Monohydrate, ciprofloxacin monohydrochloride | HMDB | | Anhydrous, ciprofloxacin hydrochloride | HMDB | | Hydrochloride, ciprofloxacin | HMDB |
|
|---|
| Chemical Formula | C17H18FN3O3 |
|---|
| Average Molecular Weight | 331.3415 |
|---|
| Monoisotopic Molecular Weight | 331.133219662 |
|---|
| IUPAC Name | 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid |
|---|
| Traditional Name | ciprofloxacin |
|---|
| CAS Registry Number | 85721-33-1 |
|---|
| SMILES | OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O |
|---|
| InChI Identifier | InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) |
|---|
| InChI Key | MYSWGUAQZAJSOK-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Quinolines and derivatives |
|---|
| Sub Class | Quinoline carboxylic acids |
|---|
| Direct Parent | Quinoline carboxylic acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinoline-3-carboxylic acid
- Fluoroquinolone
- N-arylpiperazine
- Aminoquinoline
- Haloquinoline
- Dihydroquinolone
- Dihydroquinoline
- Pyridine carboxylic acid
- Pyridine carboxylic acid or derivatives
- Tertiary aliphatic/aromatic amine
- Dialkylarylamine
- Aryl fluoride
- Aryl halide
- 1,4-diazinane
- Piperazine
- Pyridine
- Benzenoid
- Vinylogous amide
- Heteroaromatic compound
- Amino acid or derivatives
- Amino acid
- Tertiary amine
- Azacycle
- Secondary amine
- Carboxylic acid derivative
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Secondary aliphatic amine
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxide
- Organohalogen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 255 - 257 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 1.35 g/L | Not Available | | LogP | 2.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.54 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.1344 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.02 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 198.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 641.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 218.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 112.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 171.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 92.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 275.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 335.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 560.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 659.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 87.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1022.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 192.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 263.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 612.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 386.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 71.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Ciprofloxacin,1TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O | 3277.6 | Semi standard non polar | 33892256 | | Ciprofloxacin,1TMS,isomer #2 | C[Si](C)(C)N1CCN(C2=CC3=C(C=C2F)C(=O)C(C(=O)O)=CN3C2CC2)CC1 | 3311.2 | Semi standard non polar | 33892256 | | Ciprofloxacin,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C)CC3)=C(F)C=C2C1=O | 3278.3 | Semi standard non polar | 33892256 | | Ciprofloxacin,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C)CC3)=C(F)C=C2C1=O | 3052.7 | Standard non polar | 33892256 | | Ciprofloxacin,2TMS,isomer #1 | C[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C)CC3)=C(F)C=C2C1=O | 3642.0 | Standard polar | 33892256 | | Ciprofloxacin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O | 3456.2 | Semi standard non polar | 33892256 | | Ciprofloxacin,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N1CCN(C2=CC3=C(C=C2F)C(=O)C(C(=O)O)=CN3C2CC2)CC1 | 3549.4 | Semi standard non polar | 33892256 | | Ciprofloxacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C(C)(C)C)CC3)=C(F)C=C2C1=O | 3686.9 | Semi standard non polar | 33892256 | | Ciprofloxacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C(C)(C)C)CC3)=C(F)C=C2C1=O | 3456.1 | Standard non polar | 33892256 | | Ciprofloxacin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)C1=CN(C2CC2)C2=CC(N3CCN([Si](C)(C)C(C)(C)C)CC3)=C(F)C=C2C1=O | 3801.3 | Standard polar | 33892256 |
|
|---|
| General References | - Brouwers JR: Drug interactions with quinolone antibacterials. Drug Saf. 1992 Jul-Aug;7(4):268-81. [PubMed:1524699 ]
- Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J: Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986 Sep;30(3):444-6. [PubMed:3777908 ]
- Hilliard JJ, Krause HM, Bernstein JI, Fernandez JA, Nguyen V, Ohemeng KA, Barrett JF: A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase. Adv Exp Med Biol. 1995;390:59-69. [PubMed:8718602 ]
- Spivey JM, Cummings DM, Pierson NR: Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy. 1996 Mar-Apr;16(2):314-6. [PubMed:8820479 ]
|
|---|